These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31151065)

  • 1. Comparison of zonisamide with non-levodopa, anti-Parkinson's disease drugs in the incidence of Parkinson's disease-relevant symptoms.
    Iwaki H; Tagawa M; Iwasaki K; Kawakami K; Nomoto M
    J Neurol Sci; 2019 Jul; 402():145-152. PubMed ID: 31151065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease.
    Grover ND; Limaye RP; Gokhale DV; Patil TR
    Indian J Pharmacol; 2013; 45(6):547-55. PubMed ID: 24347760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease.
    Ueno SI; Saiki S; Fujimaki M; Takeshige-Amano H; Hatano T; Oyama G; Ishikawa KI; Yamaguchi A; Nojiri S; Akamatsu W; Hattori N
    Cells; 2018 Dec; 8(1):. PubMed ID: 30597973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
    Matsunaga S; Kishi T; Iwata N
    J Alzheimers Dis; 2017; 56(4):1229-1239. PubMed ID: 28157097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study.
    Murata M; Odawara T; Hasegawa K; Iiyama S; Nakamura M; Tagawa M; Kosaka K
    Neurology; 2018 Feb; 90(8):e664-e672. PubMed ID: 29367449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zonisamide has beneficial effects on Parkinson's disease patients.
    Murata M; Horiuchi E; Kanazawa I
    Neurosci Res; 2001 Dec; 41(4):397-9. PubMed ID: 11755227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Parkinson's Disease: amantadine, zonisamide, dabrafenib].
    Okamoto T
    Brain Nerve; 2019 Sep; 71(9):953-959. PubMed ID: 31506397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.
    Jing XZ; Yuan XZ; Luo X; Zhang SY; Wang XP
    Curr Neuropharmacol; 2023; 21(8):1806-1826. PubMed ID: 35193486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When do the symptoms of autonomic nervous system malfunction appear in patients with Parkinson's disease?
    De Luka SR; Svetel M; Pekmezović T; Milovanović B; Kostić VS
    Vojnosanit Pregl; 2014 Apr; 71(4):346-51. PubMed ID: 24783414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of switching from dopamine agonists to zonisamide on psychiatric and motor symptoms in patients with Parkinson's disease].
    Abe T; Maruyama H
    Rinsho Shinkeigaku; 2021 Jul; 61(7):449-455. PubMed ID: 34148934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.
    Bay AA; Hart AR; Michael Caudle W; Corcos DM; Hackney ME
    J Neurol Sci; 2019 Jan; 396():262-265. PubMed ID: 30537631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wearing off: A complex phenomenon often poorly recognized in Parkinson's disease. A study with the WOQ-19 questionnaire.
    Pistacchi M; Gioulis M; Sanson F; Marsala SZ
    Neurol India; 2017; 65(6):1271-1279. PubMed ID: 29133700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide association study identifies zonisamide responsive gene in Parkinson's disease patients.
    Cha PC; Satake W; Ando-Kanagawa Y; Yamamoto K; Murata M; Toda T
    J Hum Genet; 2020 Aug; 65(8):693-704. PubMed ID: 32355309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study.
    Ikeda K; Yanagihashi M; Miura K; Ishikawa Y; Hirayama T; Takazawa T; Kano O; Kawabe K; Mizumura N; Iwasaki Y
    J Neurol Sci; 2018 Aug; 391():5-9. PubMed ID: 30103971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world pharmacological treatment patterns of patients with young-onset Parkinson's disease in Japan: a medical claims database analysis.
    Kasamo S; Takeuchi M; Ikuno M; Kawasaki Y; Tanaka S; Takahashi R; Kawakami K
    J Neurol; 2019 Aug; 266(8):1944-1952. PubMed ID: 31076875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Solla P; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Zangaglia R; Bentivoglio A; Eleopra R; Gualberti G; Melzi G; Antonini A
    J Neurol; 2019 Sep; 266(9):2164-2176. PubMed ID: 31134377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group.
    Growdon JH; Kieburtz K; McDermott MP; Panisset M; Friedman JH
    Neurology; 1998 May; 50(5):1327-31. PubMed ID: 9595982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease: A review.
    Radhakrishnan DM; Goyal V
    Neurol India; 2018; 66(Supplement):S26-S35. PubMed ID: 29503325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.